Compare DNOW & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNOW | RDY |
|---|---|---|
| Founded | 1862 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 11.6B |
| IPO Year | N/A | N/A |
| Metric | DNOW | RDY |
|---|---|---|
| Price | $14.28 | $14.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $17.33 | $16.90 |
| AVG Volume (30 Days) | ★ 2.0M | 954.3K |
| Earning Date | 11-05-2025 | 01-22-2026 |
| Dividend Yield | N/A | ★ 0.51% |
| EPS Growth | N/A | ★ 9.95 |
| EPS | ★ 0.87 | 0.79 |
| Revenue | $2,432,000,000.00 | ★ $3,851,623,984.00 |
| Revenue This Year | $21.66 | $6.16 |
| Revenue Next Year | $92.38 | $2.57 |
| P/E Ratio | ★ $16.39 | $17.82 |
| Revenue Growth | 3.18 | ★ 14.10 |
| 52 Week Low | $12.01 | $12.26 |
| 52 Week High | $18.45 | $16.17 |
| Indicator | DNOW | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 50.98 |
| Support Level | $13.75 | $13.64 |
| Resistance Level | $14.49 | $14.21 |
| Average True Range (ATR) | 0.36 | 0.17 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 83.13 | 64.04 |
Dnow Inc is a company engaged in world-wide supplying of energy and industrial products and packaged, engineered process and production equipment with a legacy of over one sixty years. It offers a broad set of supply chain solutions combined with a suite of digital solutions branded as DigitalNOW that provide customers world-class technology for digital commerce, data and information management. Its locations provide products and solutions to exploration and production companies, midstream transmission and storage companies, refineries, chemical companies, utilities, mining, municipal water, manufacturers, engineering and construction companies. The Company has three reportable segments being United States, Canada and International.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.